• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » In India, A Pairing Born Of Necessity

In India, A Pairing Born Of Necessity

October 9, 2006
CenterWatch Staff

India’s clinical research market entered a new era in January 2005 with the signing of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. TRIPS requires the country to honor all product patents issued after 1995.

A paper published by the U.S.-based National Bureau estimates that in the antibiotic sector alone, TRIPS will result in a $713 million loss to the Indian economy; $50 million of this amount represents foregone profits of domestic drug companies. To avoid these losses, Indian pharmaceutical companies are looking for new revenue streams. Increasingly, large domestic—formerly generic—pharmaceutical companies are focusing on new drug development.

A partnership deal made last week reflects the changes going on in India’s domestic pharmaceutical market. A contract research organization (CRO) called ClinTec International, based in the UK with operations in 27 countries in Europe, South Africa, the Middle East and India, has formed a co-development partnership with Hyderabad, India-based Dr. Reddy’s Laboratories. The risk-sharing agreement involves co-development of DRF 1042, a topoisomerase inhibitor that has shown potential as an anti-cancer treatment.

Risk-sharing agreements between big pharma and CROs are rare. Two global CROs—Quintiles and PPD—have made them. More recently, a small Croatia-based CRO, Ergomed, has entered one. It remains to be seen if this is a trend that will take hold in countries where clinical research is an emerging market.

Typically, CROs provide outsourced services, project management, site selection, data management, etc., on a contract basis for a set fee whether a drug compound is successful or not. A risk-sharing agreement is more collaborative and both parties invest their time and resources in developing a drug compound for approval. The risk for the CRO is that it will not be paid for its services, but if the drug is approved the potential gains can far exceed any fees it would have received. A risk-sharing agreement makes sense for a large generic pharma company dipping its toe into clinical research development.

Dr. Reddy’s has completed phase I trials of the compound in India. Even though the country’s regulations governing clinical research have become more harmonized with international standards, first-in-man phase I studies are still not allowed in India unless the molecule was developed in the country. This could give domestic big pharma in India an edge over competitors from the West in terms of a potential drug’s time to market.

Under the terms of the agreement, ClinTec will be granted the commercialization rights for all major European markets. Dr. Reddy’s retains the commercialization rights for the U.S. and the rest of world markets, excluding ClinTec territories. On commercialization of the product, Dr. Reddy’s will receive royalty on sales by ClinTec in its designated territories and ClinTec will receive royalty on sales by Dr. Reddy’s in the U.S. Dr. Reddy’s will also retain the exclusive rights to supply commercial quantities of the drug product.

Dr. Reddy’s and Ranbaxy are India’s two largest domestic pharmaceutical companies. According to the India Brand Equity Foundation, they each have five compounds in the preclinical stage. Given their infrastructure and financial incentives, these two big pharmas could become a formidable force in the global pharmaceutical market. GV Prasad, CEO of Dr. Reddy’s, has stated unequivocally that he considers the co-development partnership with ClinTec to be “a step forward in our efforts to transform ourselves into a discovery-led global pharmaceutical company.”

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing